Your browser doesn't support javascript.
loading
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Bögemann, Martin; Shore, Neal D; Smith, Matthew R; Tammela, Teuvo L J; Ulys, Albertas; Vjaters, Egils; Polyakov, Sergey; Jievaltas, Mindaugas; Luz, Murilo; Alekseev, Boris; Lebret, Thierry; Schostak, Martin; Verholen, Frank; Le Berre, Marie-Aude; Srinivasan, Shankar; Ortiz, Jorge; Mohamed, Ateesha F; Sarapohja, Toni; Fizazi, Karim.
  • Bögemann M; Department of Urology, Münster University Medical Center, Münster, Germany. Electronic address: martin.boegemann@ukmuenster.de.
  • Shore ND; Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.
  • Smith MR; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Tammela TLJ; Tampere University Hospital and Tampere University, Tampere, Finland.
  • Ulys A; Institute of Oncology, Vilnius University, Vilnius, Lithuania.
  • Vjaters E; Department of Urology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
  • Polyakov S; Department of Urology, N.N. Alexandrov National Cancer Centre, Minsk, Belarus.
  • Jievaltas M; Department of Urology, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania.
  • Luz M; Hospital Erasto Gaertner, Curitiba, Brazil.
  • Alekseev B; Hertsen Moscow Oncology Research Institute, Moscow, Russia.
  • Lebret T; Hopital Foch, Suresnes, France.
  • Schostak M; University Hospital Magdeburg, Magdeburg, Germany.
  • Verholen F; Bayer Consumer Care AG, Basel, Switzerland.
  • Le Berre MA; Bayer HealthCare, Loos, France.
  • Srinivasan S; Bayer HealthCare, Whippany, NJ, USA.
  • Ortiz J; Bayer HealthCare, Whippany, NJ, USA.
  • Mohamed AF; Bayer HealthCare, Whippany, NJ, USA.
  • Sarapohja T; Orion Corporation Orion Pharma, Espoo, Finland.
  • Fizazi K; Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
Eur Urol ; 83(3): 212-221, 2023 03.
Article en En | MEDLINE | ID: mdl-36089529
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antígeno Prostático Específico / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials Límite: Humans / Male Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antígeno Prostático Específico / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials Límite: Humans / Male Idioma: En Año: 2023 Tipo del documento: Article